Kynamro (mipomersen) for homozygous familial hypercholesterolemia (HoFH) overcame testimony about liver problems, cancer in mice, possible cardiac risk, troubling immune responses and significant trial dropout rates to win a vote recommending approval from an FDA advisory panel.